First Light Acquisition in a press release said today’s shareholder meeting to vote on the proposed merger with calidi biotherapeutics has been adjourned until Aug. 28 at 10:30 a.m. Eastern. The meeting was previously scheduled for Aug. 22 and postponed until today.
The target is focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs.
As announced in January, the deal has a pro forma enterprise valuation of approximately $335 million.
This is Calidi’s second attempt to go public via a SPAC transaction. Edoc Acquisition called off its plan of merger with Calidi a year ago. Edoc in May 2022 had lowered the aggregate value of the consideration to Calidi from $400 million to $380 million. Read more.
Source: First Light Acquisition Adjourns Calidi Vote Again
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://spacfeed.com/first-light-acquisition-adjourns-calidi-vote-again
